I've been a part of a lot of sales training curriculum builds over the years. They usually follow a familiar arc: product features, approved messaging, objection handling, a few role plays, and a field ride with a manager who's also trying to remember everything they just learned.
But somewhere along the way, we can lose sight of what makes a rep truly effective: understanding the science and the clinical reality behind the product. In other words, scientific fluency—not just message fluency.
The need for that depth is becoming more apparent. According to Deloitte's 2024 survey of biopharma leaders, up to 80% of healthcare professionals (HCPs) are skeptical about the scientific validity of pharma communications, and roughly half report experiencing content fatigue from the volume of outreach they receive.
Additionally, HCPs are increasingly selective about which companies they give their time to, with more than 50% of HCPs meeting with reps from three or fewer companies and more specifically, a figure that rises to 55% in oncology.¹˒²
The window is narrower, the bar for earning an HCP’s time and attention is higher, and a rep who walks in with a script is not clearing that bar.
The access problem is really an attention problem
The data isn't saying HCPs don't want to hear from reps. It's saying they want a different kind of conversation. HCPs increasingly turn to digital sources for clinical information, while AI is making it easier than ever to synthesize evidence, competitor data, and treatment guidelines before a rep walks through the door.
The bar for adding value in that room has never been higher, and most training programs haven't caught up.
Closing that gap requires reps who understand the science well enough to have a genuine conversation and not just deliver a detail. The most effective sales representatives stand out because they focus on people, not products. That shift doesn't happen through better messaging. It happens when a rep understands the disease, the patient journey, and the clinical context well enough to add something to the HCP's thinking rather than just presenting at them.
Understanding the why behind the message
Here's where a lot of sales training falls short (whether it’s due to rushing to get reps in the field or something else): it starts with the message and works down to the science. Reps learn what to say, then learn the data that supports it.
The problem is that when reps learn the message before they understand the science behind it, the message becomes a script rather than a conviction. A clinician who has read the same trial data, attended congress presentations, and has increasingly used AI tools synthesizing the clinical literature before a rep walks in can feel the difference immediately.
When a rep understands why a particular endpoint was chosen, why the dosing schedule is what it is, why the clinical narrative is framed the way it is, the approved message stops being a constraint and starts being a tool. They can use it more flexibly, more confidently, and more credibly. The message becomes the synthesis of their clinical understanding, not the starting point for it.
Scientific fluency, however, isn't the same as knowing more science. A rep can memorize a mechanism of action, trial endpoints, efficacy data and safety profile and still struggle to use that knowledge in a conversation. Fluency is the ability to connect the science to the patient, the clinical decision, the evidence and, ultimately, the question in front of them. It's knowing what matters, why it matters, and how the pieces connect.
That reframe changes everything about how reps show up in a room. Why? Because the pacing is different; the questions they ask are different; and the ability to handle an unexpected follow-up without losing the thread is different.
How to build it: a layered approach
The approach to this is key. Usually, organizations either frontload so much clinical content that reps are overwhelmed before they've learned to walk, or they bolt scientific depth on as an advanced module that only the most curious reps engage with. Neither approach actually works.
The approach that does work is layered; building knowledge progressively from disease and patient context to clinical application. Clinical immersion isn't about adding more science to the curriculum. It's about changing where the science sits in the learning experience.
Phase 1: Build the clinical foundation. Before reps learn the message, they learn the disease. Patient profiles, disease burden, how diagnosis happens, what treatment decisions look like from the HCP's chair. This isn't a deep scientific lecture. It's enough context to make everything that comes next meaningful rather than abstract. When reps understand the problem first, the solution lands differently, and so does every conversation they'll have about it in the field.
Phase 2: Connect the science to the message. Product training happens but with the clinical foundation already in place, it's taught differently. Instead of "here's the claim and here's the supporting data," it becomes: here's what's happening at the biological level, here's what the trial measured and why those endpoints matter to a clinician, and here's how that translates into what you'll say in the room. Reps aren't memorizing claims – they're making connections.
Phase 3: Practice clinical synthesis. Before reps go to the field, they need an opportunity to pull everything together. To take the clinical knowledge, the product training, and the approved messaging and practice integrating them in realistic scenarios, not role plays where they recite the detail. We’re talking about conversations where they must think, respond, and connect the dots in real time and under the pressure of a skeptical HCP who has three minutes and a waiting room full of patients. This is where scientific knowledge becomes clinical fluency and where clinical fluency becomes conversational confidence. This is the step most often cut when timelines get tight, which is precisely why so many reps arrive in the field technically certified but not actually ready.
Phase 4: Reinforce in the field. Scientific fluency doesn't hold without reinforcement. The managers and coaches who sustain it are the ones who debrief with questions like "what do you think was driving that objection clinically?" rather than "did you hit all your key messages?" The coaching conversation must reflect the same depth as the training program, otherwise the field quickly reverts to script.
What this means for the access problem
The narrowing HCP access window doesn't make scientific fluency a nice-to-have. It makes it the prerequisite for earning the next conversation.
The goal isn't to turn sales reps into scientists. It's to equip them with enough clinical understanding to recognize what matters to the HCP in front of them, connect the science to the patient and treatment decision, and make the approved message relevant rather than rehearsed.
While access gets a rep into the room, scientific fluency is what helps them add value once they're there.
Clinical immersion shouldn't be treated as another content module to complete before launch. It should be a training philosophy; one that builds the disease, patient, clinical, and scientific context reps need to use their commercial capabilities effectively.
At OCTANE, we design training programs that build scientific fluency from the ground up—connecting clinical depth to commercial capability in a way that prepares reps for the conversations HCPs actually want to have.
References
MM&M. (2022). The return of rep access: Report suggests bounce-back in rate of pharma-friendly docs.
Fox, J., Elsner, N., & Jobanputra, D. (2025). Navigating the future of commercial in biopharma. Deloitte Center for Health Solutions.
